What happens if intradermal injections of rabies vaccine are partially or entirely injected subcutaneously?
Bulletin of the World Health Organization (WHO)
; 68(1): 83-5, 1990. Tab
Article
in English
| PAHO
| ID: pah-7337
Responsible library:
US1.1
Localization: US1.1, WHO COLL
ABSTRACT
Reported are the results of a study with the Thai Red Cross two-site intradermal purified Vero-cell rabies vaccine (PVRV) schedule that was deliverately injected into subcutaneous tissue. The 44 healthy nonimmune Thai adults who were enrolled in the study were randomly assigned to the following groups and given PVRV as shown group A (two intradermal injections on days 0, 3, and 7); group B (one intradermal and one subcutaneous injection on days 0, 3, and 7); and group C (two subcutaneous injections on days 0, 3, and 7). Neutralizing antirabies antibody titres were determined on day 14 using the rapid fluorescent focus inhibition test. High rabies antibody titres were obtained for all three groups
Search on Google
Collection:
Databases of international organizations
Health context:
Sustainable Health Agenda for the Americas
/
Neglected Diseases
Health problem:
Goal 5: Medicines, vaccines and health technologies
/
Neglected Diseases
/
Zoonoses
Database:
PAHO
Main subject:
Rabies virus
/
Injections, Intradermal
/
Rabies Vaccines
/
Injections, Subcutaneous
/
Antibodies, Viral
Type of study:
Controlled clinical trial
Country/Region as subject:
Asia
Language:
English
Journal:
Bulletin of the World Health Organization (WHO)
Year:
1990
Document type:
Article